

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

VOLUNTARY ANNOUNCEMENT

UPDATE ON PROPOSED INCREASE IN SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER AND DIRECTOR

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 20 July 2026 in relation to the intention of Mr. Zhang Yushuai (“**Mr. Zhang**”), the controlling shareholder and non-executive director of the Company (the “**Director(s)**”), to increase his shareholding in the Company through purchasing shares of the Company (“**Shares**”) listed on The Stock Exchange of Hong Kong Limited in the open market by or through entities controlled by him.

The board of directors of the Company (the “**Board**”) has been notified by Mr. Zhang that during the period between 24 July 2026 and 30 July 2026, Mr. Zhang had purchased a total of 1,451,400 H Shares from the open market for an aggregate consideration of approximately HK\$56,000,000 (the “**Purchases**”). As of the date of this announcement and immediately after the Purchases, Mr. Zhang directly and indirectly holds an aggregate of 295,423,156 Shares, representing approximately 51.42% of the total issued Shares (excluding treasury Shares).

As advised by Mr. Zhang, he is confident in the Group’s long-term development prospects and intrinsic values, and will look to further increase his shareholding in the Company subject to market conditions.

Based on information available to the Company and to the best knowledge and belief of the Directors, following the Purchases made by Mr. Zhang, the Company has maintained a sufficient public float of issued Shares that satisfies the requirements under with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
30 July 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.